Pharmaceutical Executive-11-01-2012

Pharm Exec's 2013 Pipeline Report

For the second time in recent memory, a top European regulator leaves office abruptly and under a cloud of suspicion.

How an agency and client behave after they split speaks volumes about their culture and character, writes Al Topin.

While the nation was embroiled in the presidential elections, a number of important legal and regulatory issues absorbed pharmaceutical executives, writes Jill Wechsler.

Providers and patients fish for that delicate balance between access and abandonment.

Over-the-counter products face a new wave of regulation.

Prix Galien celebrates a new round of next generation drug technologies.

Commercial teams as well as patients can benefit from managed access programs.

Spain's leading business school, IESE, organized an expert conference on October 2-3 to address two simple questions. First, how can providers and payers work together to generate more value from existing resources? Second, what must be done to ensure the system continues to create value in the first place?

Unified payer research planning is of top import.

Is the 'lost decade' of declining pipeline productivity finally over? Our annual survey of analyst assessments of the state of drug development suggests so...

The '90s was an enthusiastic time. With the fall of communism in 1989 and the emergence of the free economy, the international pharmaceutical industry arrived in the Czech Republic to find a highly receptive market.

Chinese start-ups have realized that they need to recruit highly skilled and globally oriented general managers from foreign multinationals when they reach a critical size.